Third Circuit Court Rules Biotech Firm Must Continue Royalties Post Patent Expiry

In a notable ruling, a Third Circuit panel has determined that a cancer drug biotechnology company is required to continue paying royalties to a research firm even after the expiration of the applicable patents. This decision is based on the panel’s conclusion that the biotech’s royalty obligation is calculated differently than in a U.S. Supreme Court case it referenced. For more details on the case, you can access the full article on Law360.